Maxim Jacobs
15 May 2017 · 3 min read

Edison KOL call

Major Depression Disorder

The sixth in our KOL series, Edison sponsors an interview with Dr. Michael Thase of the Perelman School of Medicine of the University of Pennsylvania.  The conversation featured a discussion on emerging depression treatments.

Read more...
Maxim Jacobs
28 March 2017

Edison KOL call

Edison KOL Call: AML

The fifth in our KOL series, Edison sponsors an interview with Dr. Douglas Smith of the Johns Hopkins University School of Medicine.  The conversation featured a discussion on emerging AML treatment.

Read more...
Maxim Jacobs
7 February 2017

Edison KOL call

PNH

The fourth in our KOL series, Edison sponsors an interview between Dr. Jaroslaw Maciejewski, Chairman of the Department of Translational Hematology and Oncology Research at the Cleveland Clinic.  The conversation featured a discussion on current and emerging PNH treatments. 

Read more...
Maxim Jacobs
21 December 2016

Edison KOL call

Conversation focus

The third in our KOL series, Edison sponsors an interview between Max Jacobs (call leader) and Dough Hillblom, President of Arena Healthcare, a strategic consultancy focusing on payers and policy makers. The conversation featured a discussion on the PBM model as well as drug pricing and formulary trends. 

Read more...
Maxim Jacobs
17 November 2016

Edison KOL call

Pediatric Epilespy

The second in our KOL series, Edison sponsors an interview between Dr Wirrell, Director of Pediatric Epilespy at the Mayo Clinic. and Max Jacobs (call leader). The conversation featured a discussion on the clinical course of various pediatric epilepsies and the place that Epidiolex might have in the treatment paradigm. 

Read more...
Maxim Jacobs
24 October 2016

Edison KOL call

CAR-T therapy

On October 19 we kicked off our KOL series, sponsoring an interview between Rafael Mejar, M.D., Ph.D and Max Jacobs (call leader). The conversation featured a discussion on the delivery challenges and potential solutions to administering CAR-T therapy more widely upon eventual FDA approvals. The discussion focused on the number of specialists needed, facility requirements and cost of delivery among other potential hurdles to use. Below is a link to a recording of the event and the transcript to the call.

Read more...